Literature DB >> 6495172

Late outcome of operations for supratentorial convexity meningiomas. Report on 207 cases.

S Giombini, C L Solero, G Morello.   

Abstract

Brief remarks on the immediate outcome of operations on 207 convexity meningiomas are followed by a fuller discussion of the late sequelae, the problem of recurrences and relevance of histology, and the persistence or de novo onset of epilepsy. While the immediate outcome is more than satisfactory, there is still room for improvement in the late outcome of surgical treatment for this category of intracranial tumor.

Entities:  

Mesh:

Year:  1984        PMID: 6495172     DOI: 10.1016/0090-3019(84)90436-1

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  5 in total

1.  The incidence of multiple meningiomas--do solitary meningiomas exist?

Authors:  B Borovich; Y Doron; J Braun; M Feinsod; D Goldsher; J Gruszkiewicz; J N Guilburd; M Zaaroor; L Levi; J F Soustiel
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

2.  Recurrences in meningioma after surgery.

Authors:  P K Gupta; V R Sastry Kolluri; S Das; B A Chandra Mouli; K S Narayana Swamy; B S Das
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

3.  Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression.

Authors:  H Nakabayashi; M Sakaguchi; J Katsuyama; A Hakuba
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

4.  Recurred Intracranial Meningioma: A Retrospective Analysis for Treatment Outcome and Prognostic Factor.

Authors:  Hyun-Seung Ryu; Kyung-Sub Moon; Kyung-Hwa Lee; Woo-Youl Jang; Tae-Young Jung; In-Young Kim; Shin Jung
Journal:  Brain Tumor Res Treat       Date:  2017-11-03

5.  Establishment of a molecular cytogenetic analysis for native tumor tissue of meningiomas-suitable for clinical application.

Authors:  Cornelia Lerner; Ralf Ketter; Stefan Linsler; Wolfram Henn; Joachim Oertel; Steffi Urbschat
Journal:  Mol Cytogenet       Date:  2014-02-05       Impact factor: 2.009

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.